Original Article

CRUSADE bleeding score as a predictor of bleeding events in patients with acute coronary syndrome in Zagazig University Hospital

Mohamed M. Al-Daydamony *, El-Sayed M. Farag

Cardiology Department, Faculty of Medicine, Zagazig University, Egypt

**A R T I C L E   I N F O**

Article history:
Received 14 January 2016
Accepted 7 March 2016
Available online 22 March 2016

Keywords:
Acute coronary syndrome
Coronary artery disease
CRUSADE bleeding risk score
Major bleeding
Egypt

**A B S T R A C T**

**Aim:** To examine the value of CRUSADE bleeding score in predicting bleeding events in our local patients with acute coronary syndrome (ACS) in Zagazig University Hospitals.

**Methods:** Our study included 240 patients with ACS. They underwent history and clinical examination; 12-lead electrocardiography; echocardiography; troponin I, hematocrit value; estimated glomerular filtration rate (eGFR); application of CRUSADE score; and follow-up of the hospital stay and documentation of events. Patients were classified into two groups: Group I: patients with major bleeding, and Group II: patients without major bleeding.

**Results:** Patients with major bleeding were significantly older, with more diabetic and hypertensive patients, more prior vascular disease, heart failure, and less patients with unstable angina, higher heart rate and systolic blood, lower eGFR, and higher CRUSADE risk score.

CRUSADE bleeding score was the strongest predictor of major bleeding. Sensitivity of CRUSADE score ≥33 in prediction of major bleeding in the whole study group was 80%, specificity was 73.4%, positive predictive value was 26.9%, negative predictive value was 96.9%, overall accuracy was 74.1%. Sensitivity of CRUSADE score ≥38.5 in prediction of major bleeding in the STEMI patients was 70%, specificity was 84.8%, positive predictive value was 50%, negative predictive value was 92.9%, and overall accuracy was 82.1%.

**Conclusion:** CRUSADE score is a good predictor for major bleeding in Egyptian patients with ACS. It is applicable in UA/NSTEMI as well as in STEMI patients and in women as well as in men.

© 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Coronary artery disease (CAD) is one of the most important leading causes of death in the whole world. Among the different clinical presentations of CAD, acute coronary syndrome (ACS) is the most important and life threatening condition. Different pathogeneses may share in the development of ACS. However, thrombosis is one of the most important.

* Corresponding author.
E-mail address: m_daydamony@hotmail.com (M.M. Al-Daydamony).

http://dx.doi.org/10.1016/j.ihj.2016.03.007
0019-4832/© 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Therefore, antithrombotic therapies represent a cornerstone in the management of patients with ACS.\(^4\)

In spite of their obvious effect, antithrombotic therapies for ACS significantly increase bleeding.\(^5\) Hence, it is important to predict the bleeding risk in ACS patients in order to modify their treatment aiming to reduce their bleeding events and improve their outcome.

Various bleeding risk scores were developed and tested. Among those, CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) is very significant. Bleeding score was found to be the most accurate in the prediction of major bleeding events.\(^6\) However, these models have not been evaluated for Egyptian situation with different patients’ characteristics and treatment patterns.

The aim of the current study was to examine the value of CRUSADE bleeding score in predicting the bleeding events in our local patients with ACS in Zagazig University Hospitals.

### 2. Methods

Our study took place in Zagazig University Hospitals during the period from September 2014 to October 2015. Our study included 240 patients with ACS (145 males and 95 females). Their age ranged from 41 to 77 years with mean age of 58.1 ± 10.48 years. Patients were included in our study if they fulfilled at least two of the following criteria:

- Presence of typical, chest pain, which is defined as retrosternal oppressive or compressive, which occurs at rest or with minimal exertion lasting for at least 10 min.\(^7\)
- Electrocardiographic changes in the form of ST-depression, ST-elevation, or new T-wave inversion.
- Positive cardiac enzymes according to the third universal definition of myocardial infarction.\(^8\)

If there were persistent ST-segment elevation ≥1 mm in at least two contiguous leads, reciprocal ST-segment depression ≥1 mm in \(V_1\) or \(V_2\), or presumed new left bundle branch block; then patients were considered as having ST-segment Elevation Myocardial Infarction (STEMI).\(^9\) If cardiac biomarkers were elevated without any of the previous ECG changes; then patients were considered as having Non-ST-segment Elevation Myocardial Infarction (NSTEMI).\(^9\) Otherwise, patients were considered as having Unstable Angina (UA).

Patient on oral anticoagulation and patient, who died or discharged within 48 h of admission were excluded from our study.

After giving an informed written consent, all patients were subjected to the following:

1) Full history taking and thorough clinical examination
2) Complete 12-leads electrocardiography
3) Echocardiography: Echocardiographic studies were performed for all patients using Philips IE33 and GE VIVID E9 machines with 2.5 MHz transducers. The left ventricular ejection fraction (LVEF) was measured using the modified Simpson’s method from the 2-dimensional apical 4-chamber view.\(^10\)
4) Laboratory testing
   The following laboratory tests were conducted on all patients:
   - Cardiac troponin I level: at presentation and 6 h after symptoms onset.\(^5\)
   - Hematocrit level: at admission, at discharge, and when there is any sign of bleeding.
   - Estimated glomerular filtration rate (eGFR) calculation: eGFR was calculated according to the Cockcroft–Gault formula.\(^11\)
5) Application of CRUSADE bleeding risk score according to the data seen in Table 1.\(^12\)
6) Treatment of patients
   All NSTEMI and UA angina patients were treated according to the ischemia-guided strategy.\(^4\) All patients received double antiplatelet therapy (aspirin and clopidogrel) and enoxaparin according to the 2014 guidelines of AHA/ACC for the management of UA/NSTEMI.
   All STEMI patients received thrombolytic therapy with streptokinase in addition to double antiplatelet (aspirin and

| Predictor                  | Range          | Score | Predictor                  | Range          | Score |
|----------------------------|----------------|-------|----------------------------|----------------|-------|
| Baseline hematocrit         | <31            | 9     | Systolic blood pressure    | 91–100         | 8     |
|                            | 31–33.9        | 7     |                            | 101–120        | 5     |
|                            | 34–36.9        | 3     |                            | 121–180        | 1     |
|                            | 37–39.9        | 2     |                            | 181–200        | 3     |
|                            | ≥201           | 5     | Heart rate                 | 71–80          | 1     |
|                            | ≥81–90         | 3     |                            | 81–90          | 3     |
|                            | 91–100         | 6     |                            | 91–100         | 6     |
|                            | 101–110        | 8     |                            | 101–110        | 8     |
|                            | 111–120        | 10    |                            | 111–120        | 10    |
|                            | ≥121           | 11    | Prior vascular disease     | No             | 0     |
|                            | Yes            | 6     |                            | Yes            | 6     |
| Diabetes mellitus           | No             | 0     | Female sex                 | No             | 0     |
|                            | Yes            | 7     |                            | Yes            | 8     |
Table 2 – Population characteristics and clinical data.

|                                | Major bleeding (n = 26) | No major bleeding (n = 214) | p       |
|--------------------------------|-------------------------|-----------------------------|---------|
| Age (years)                    | 65.1 ± 5.51             | 57.3 ± 10.64                | <0.00001|
| Sex                            |                         |                             |         |
| Male                           | 14 (53.8%)              | 131 (61.2%)                 | 0.468   |
| Female                         | 12 (42.2%)              | 83 (38.8%)                  |         |
| Weight (kg)                    | 78.7 ± 10.94            | 82.3 ± 14.36                | 0.128   |
| Diabetes                       | 23 (88.5%)              | 60 (28%)                    | <0.00001|
| Hypertension                   | 18 (69.2%)              | 57 (26.4%)                  | <0.00001|
| Smoking                        | 3 (11.5%)               | 44 (20.6%)                  | 0.274   |
| Dyslipidemia                   | 7 (26.9%)               | 33 (15.4%)                  | 0.137   |
| Prior vascular disease         | 19 (73.1%)              | 44 (20.6%)                  | <0.00001|
| Prior myocardial infarction    | 6 (23.1%)               | 41 (19.2%)                  | 0.635   |
| Prior coronary revascularization| 3 (11.5%)              | 53 (24.8%)                  | 0.132   |
| Heart failure on admission     | 12 (46.2%)              | 45 (21%)                    | 0.004   |
| ACS type                       |                         |                             |         |
| -UA                            | 4 (15.4%)               | 88 (41.1%)                  | 0.011   |
| -NSTEMI                        | 12 (46.2%)              | 80 (37.4%)                  | 0.366   |
| -STEMI                         | 10 (38.4%)              | 46 (21.5%)                  | 0.055   |
| Heart rate (beat/min)          | 100.1 ± 22.55           | 88 ± 15.8                   | 0.0084  |
| Systolic blood pressure (mmHg) | 150.8 ± 21.52           | 127.1 ± 25.78               | <0.00001|
| Baseline hematocrit (%)        | 3.9 ± 6.12              | 40.3 ± 4.35                 | 0.259   |
| eGFR (ml/min)                  | 66.5 ± 30.02            | 96.7 ± 32.37                | <0.00001|
| CRSUADE score                  | 44.7 ± 11.67            | 28.3 ± 11.93                | <0.00001|
| CRSUADE score >33             | 18 (69.2%)              | 61 (28.5%)                  | <0.00001|
| Ejection fraction (%)          | 57.2 ± 8.61             | 62.1 ± 9.31                 | 0.0071  |

As shown in Table 2, there was no significant difference between the study groups concerning sex, weight, smoking, dyslipidemia, prior myocardial infarction, prior coronary revascularization, or baseline hematocrit value.

Patients with major bleeding were significantly older than patients without major bleeding (p < 0.00001). There were significantly more diabetic, more hypertensive, and more patients with prior vascular disease among major bleeding group (p < 0.00001 for each). Prior vascular disease was defined according to the CRSUADE registry (prior stroke and/or peripheral artery disease).

On hospital admission, there were significantly more patients in heart failure among major bleeding group (p < 0.00001).

Regarding the type of ACS, there were significantly less patients presented with UA among major bleeding group (p = 0.011).

At presentation, patients with major bleeding had significantly higher heart rate (p = 0.0084) and systolic blood pressure (p < 0.00001).

The eGFR was significantly lower in patients with major bleeding than (p < 0.00001). Also, LVEF was significantly lower in (p = 0.0071).

The CRSUADE score was significantly higher in patients with major bleeding (p < 0.00001). Also, there were more
patients with CRUSADE score ≥33 among patients with major bleeding (p < 0.00001).

Regarding in-hospital outcome, as shown in Table 3, there was no significant difference between the two groups regarding death, developing cardiogenic shock, or doing CABG.

In patients with major bleeding, more patients developed heart failure during hospital stay (p = 0.013). Also, more patients had undergone PCI during hospital stay (p = 0.029).

Regression analysis of the relation of different parameters to the development of major bleeding is shown in Table 4. CRUSADE bleeding score was the strongest independent predictor of major bleeding (p < 0.00001). Other significant independent predictors were in order of significance: diabetes mellitus, prior vascular disease, basal hematocrit, hypertension, eGFR (p < 0.00001 for each), systolic blood pressure (p = 0.00034), age (p = 0.00052), heart rate (p = 0.0015), and heart failure during hospital stay (p = 0.0013).

The validity of CRUSADE score ≥33 in prediction of major bleeding in the whole study group is shown in Table 5. Sensitivity of was 80%, specificity was 73.4%, positive predictive value was 26.9%, negative predictive value was 96.9%, and overall accuracy was 74.1%, p = 0.0013. The receiver operating characteristic (ROC) curve analysis is shown in Fig. 1, and area under ROC-curve is 0.85.

The validity of CRUSADE score ≥38.5 in prediction of major bleeding among STEMI patients is shown in Table 6. Sensitivity of was 70%, specificity was 84.8%, positive predictive value was 50%, negative predictive value was 92.9%, and overall accuracy was 82.1%, p = 0.00021. The ROC curve analysis is shown in Fig. 2, and area under ROC-curve was 0.79.

The validity of CRUSADE score ≥36 in prediction of major bleeding among women is shown in Table 7. Sensitivity of was 66.7%, specificity was 89.2%, positive predictive value was 47.1%, negative predictive value was 94.9%, and overall accuracy was 86.3%, p = 0.00008. The ROC curve analysis is shown in Fig. 3, area under ROC-curve was 0.89.

The rates of major bleeding in different CRUSADE score groups are shown in Table 8. The rate of bleeding was 3.4% in patients with very low risk (score ≤20), 5.6% in patients with low risk (score 21–30), 12.1% in patients with moderate risk (score 31–40), 25.8% in patients with high risk (score 41–50), and was 35.3% in patients with very high risk (score ≥50).

### 4. Discussion

Hemorrhagic complications are the most common non-ischemic complications encountered in patients with ACS. The frequency of major hemorrhaging oscillates between 2%...
Table 6 – Validity of CRUSADE score in prediction of major bleeding in STEMI patients.

|                  | Major bleeding | No major bleeding | Total |
|------------------|----------------|-------------------|-------|
| CRUSADE < 38.5   | 3              | 39                | 42    |
| CRUSADE ≥ 38.5   | 7              | 7                 | 14    |
| Total            | 10             | 46                | 56    |

Sensitivity | Specificity | PPP | NPV | Overall accuracy | Kappa | p
70%         | 84.8%        | 50% | 92.9% | 82.1%           | 0.47   | 0.000021

PPV, positive predictive value; NPV, negative predictive value.

Table 7 – Validity of CRUSADE score in prediction of major bleeding in women.

|                  | Major bleeding | No major bleeding | Total |
|------------------|----------------|-------------------|-------|
| CRUSADE < 36     | 4              | 74                | 78    |
| CRUSADE ≥ 36     | 8              | 9                 | 17    |
| Total            | 12             | 83                | 95    |

Sensitivity | Specificity | PPP | NPV | Overall accuracy | Kappa | p
66.7%       | 89.2%        | 47.1% | 94.9% | 86.3%           | 0.53   | 0.000008

PPV, positive predictive value; NPV, negative predictive value.

Fig. 2 – ROC curve for CRUSADE score with major bleeding events in STEMI population.

Fig. 3 – ROC curve for CRUSADE score with major bleeding events in women.

and 9% across the spectrum of ACS without ST-segment elevation, largely depending on the definition and the type of treatment used, particularly the dose of antithrombotic agents prescribed and the invasive procedures undertaken. Moreover, the present study was done to test the validity of the CRUSADE bleeding risk model in the prediction of major bleeding in Egyptian patients with ACS, either UA/NSTEMI or STEMI.

Although the CRUSADE score was developed by using the database of patients with high-risk non-ST-elevation ACSs admitted in American hospitals, of whom only less than 1% were of Middle Eastern origins, our results showed that the validity of the CRUSADE bleeding risk model in Egyptian patients with ACS was more or less satisfactory, either in patients with UA/NSTEMI or STEMI.

Several published studies demonstrated successful use of CRUSADE score in the prediction of major bleeding in different populations with ACS from various Western countries. Abu-Assi et al. evaluated the validity of the CRUSADE bleeding risk score in a cohort of 782 hospitalized patients with UA/NSTEMI in a Spanish population. They have found that The CRUSADE risk score was generally validated and found to be useful in the Spanish cohort of patients treated with or without multiple antithrombotic therapy either they underwent cardiac catheterization or not.

Also, Kharchenko and his colleagues had studied the prognostic value of CRUSADE bleeding risk score in 602 patients...
with UA/NSTEMI, who were admitted to a Moscow community noninvasive hospital. They found sensitivity and specificity of the CRUSADE score for major and moderate bleedings during hospitalization were 77% and 52%, respectively; with area under ROC-curve was 0.68.17

Boden et al. had studied the risk of in-hospital major CRUSADE bleeding and 1-year mortality after primary PCI for 965 Dutch STEMI patients, who received abciximab, periprocedural heparin, and loading doses of aspirin and clopidogrel. They had found that major bleeding was common after primary PCI for STEMI and associated with increased mortality during 1-year follow-up. However, they found that the CRUSADE bleeding risk score had underestimated the risk of major bleeding, and they concluded that the use of this score might be limited in STEMI patients.18

The CRUSADE bleeding risk score has been evaluated not only in North America and Western Europe, but also in the Far East. Jinatongthai et al. had studied the validity of CRUSADE score in predicting major bleeding in Thai patients with ACS receiving enoxaparin. They had found that the CRUSADE model demonstrated a satisfactory discriminatory capacity for the entire study population (C = 0.688), UA (C = 0.591), NSTEMI (C = 0.693), and STEMI groups (C = 0.736). They concluded that CRUSADE risk score was able to estimate in-hospital major bleeding of Thai patients with ACS, who received treatment with enoxaparin.19

The wide applicability of CRUSADE risk score in an extensive range of population may be explained by many reasons. The score was developed from a very large patient registry from a real-life practice, so its variables were widely applicable in many different situations. Many variables in CRUSADE, such as female gender, low baseline hematocrit, and presence of organ failure such as heart or kidney failure were commonly identified and used by other bleeding risk models.20,21

Although we have found that CRUSADE risk score was a good predictor of major bleeding in the whole group and in STEMI subgroup, however, we did not find significant difference between patients with and without major bleeding regarding hospital mortality. This result was discordant to the results found by Amador et al., as they found a strong relation between major bleeding and hospital mortality. They also found that CRUSADE bleeding risk score was as valid as ischemia risk score like TIMI and GRACE risk scores in predicting mortality.22

The rates of bleeding in our study were higher than those found by the original CRUSADE investigators.12 These differences were much obvious among patients with high risk (25.8% in our results versus 11.9% in CRUSADE), and among patients with very high risk (35.3% in our results versus 19.5% in CRUSADE). These differences may be explained by the center, where the study was done, Zagazig University Hospital, which is a tertiary hospital to which patients with more severe diseases and co-morbidities are referred. Other possible explanation is the endemic diseases that are more common in Egypt and may affect the coagulation profile like hepatitis C virus (HCV), as the highest prevalence of HCV infection around the world was found to be in Egypt (15–20%), while its global prevalence was found to be 2.2%.23

5. Conclusion

- CRUSADE bleeding risk score is a good predictor for major bleeding among Egyptian patients with ACS.
- Application of CRUSADE bleeding risk score may be helpful in Egypt.
- The risk was found to be applicable in UA/NSTEMI as well as in STEMI patients, and in women as well as in men.

Study limitations

- Relatively small number of patients.
- The study was done in a single center.

Conflicts of interest

The authors have none to declare.

REFERENCES

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747−1757.
2. Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA. The Global Registry of Acute Coronary Events, 1999 to 2009−GRACE. Heart. 2010;96:1095−1101.
3. Hamm CW, Möllmann H, Bassand JP, Van deWerf F. Acute coronary syndrome. In: Camm AJ, Lüscher TF, Serruys PW, eds. In: The ESC Textbook of Cardiovascular Medicine 2nd ed. Oxford: Oxford University Press; 2009.
4. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64:e139−e228.
5. Lopes RD, Alexander KP, Manoukian SV, et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;53:1021−1030.
6. Flores-Rios X, Couto-Mallón D, Rodríguez-Garrido J, et al. Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding risk scores in STEMI undergoing primary PCI: insights from a cohort of 1391 patients. Eur Heart J Acute Cardiovasc Care. 2013;2:19−26.
7. Sabatine MS, Cannon CP. Approach to the patient with chest pain. In: Benow RO, Braunwald E, eds. In: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine 9th ed. Philadelphia, PA: Elsevier/Saunders; 2012:1076−1086.
8. Thyesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Joint ESC/ACC/AHA/WHF Task Force for the universal definition of myocardial infarction. Third universal definition of myocardial infarction. Circulation. 2012;126:2020−2035.
9. Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in
the interpretation of troponin elevations: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2012;60:2427–2463.

10. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79–108.

11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.

12. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation. 2009;119:1873–1882.

13. O’Gara PT, Kushner FG, Asheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529–555.

14. Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM, Bassand JP. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1193–1204.

15. Taha S, D’Ascenzo F, Moretti C, et al. Accuracy of bleeding scores for patients presenting with myocardial infarction: a meta-analysis of 9 studies and 13,759 patients. Postepy Kardiol Interwencyjnej. 2015;11:182–190.

16. Abu-Assi E, Gracia-Acuña JM, Ferreira-González I, Peña-Gil C, Gayoso-Díaz F, González-Juanatey JR. Evaluating the performance of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) bleeding score in a contemporary Spanish cohort of patients with non-ST-segment elevation acute myocardial infarction. Circulation. 2010;121:2419–2426.

17. Kharchenko MS, Erlikh AD, Gratsianskii NA. Assessment of the prognostic value of the CRUSADE score in patients with acute coronary syndromes hospitalized in a noninvasive hospital. Kardiologiya. 2012;52:27–32.

18. Boden H, Velders M, van der Hoeven BL, Schalij MJ. TCT-557 the risk of in-hospital bleeding and long-term mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2012;60:.

19. Jinatongthai P, Khaisombut N, Likittanasombat K, Chaiyakunapruk N, Watcharathanakij S, Nathisuwan S. Use of the CRUSADE bleeding risk score in the prediction of major bleeding for patients with acute coronary syndrome receiving enoxaparin in Thailand. Heart Lung Circ. 2014;23:1051–1058.

20. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556–2566.

21. Mrdovic I, Savic L, Krjanac G, et al. Simple risk algorithm to predict serious bleeding in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: RISK-PCI bleeding score. Circ J. 2013;77:1719–1727.

22. Amador P, Santos JF, Gonçalves S, Seixo F, Soares L. Comparison of ischemic and bleeding risk scores in non-ST elevation acute coronary syndromes. Acute Card Care. 2011;13:68–75.

23. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436–2441.